Logo

SIMAU

SIM Acquisition Corp. I Unit

SIMAU

SIM Acquisition Corp. I Unit • NASDAQ
$10.80 ▲ 0.00% (+0.00)
Market Cap $304.46 M
52w High $11.91
52w Low $10.01
Dividend Yield 0%
P/E 0
Volume 100
Outstanding Shares 31.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $258.011K ▲ $2.252M ▼ 0% $0.07 ▼ $0 ▲
Q2-2025 $0 $181.535K ▼ $2.298M ▲ 0% $0.075 ▲ $-181.535K ▲
Q1-2025 $0 $241.472K ▼ $2.223M ▼ 0% $0.072 ▼ $-241K ▼
Q4-2024 $0 $264.21K ▼ $2.431M ▲ 0% $0.12 $2.695M ▲
Q3-2024 $0 $270.193K $2.357M 0% $0.12 $193

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $169.145K ▼ $243.11M ▲ $10.95M $-10.559M ▼
Q2-2025 $346.169K ▼ $240.822M ▲ $10.95M ▼ $-10.301M ▼
Q1-2025 $511.697K ▼ $238.557M ▲ $10.99M ▲ $227.567M ▲
Q4-2024 $697.085K ▼ $236.327M ▲ $10.983M ▲ $225.344M ▲
Q3-2024 $860.086K $233.873M $10.96M $-9.614M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $4.473M ▲ $-177.024K ▼ $0 $0 $-177.024K ▼ $-177.024K ▼
Q2-2025 $2.298M ▲ $-165.528K ▲ $0 $0 $-165.528K ▲ $-165.528K ▲
Q1-2025 $2.222K ▲ $-185.388K ▼ $0 ▼ $0 ▲ $-185.388K ▼ $-185.388K ▼
Q4-2024 $-2.319K ▼ $680.934 ▲ $230K ▲ $-231.541K ▼ $-163 ▼ $680.934 ▲
Q3-2024 $2.357K $-500 $-230K $231.341M $840.834 $-500

Five-Year Company Overview

Income Statement

Income Statement SIMAU currently has no operating business, so its income statement is more of a formality than a reflection of an ongoing company. There is no revenue, no gross profit, and no real operating activity yet. Any earnings per share figure at this stage mainly reflects the way the IPO and trust structure are accounted for, not the profitability of a normal business. The real economic story will only begin once a merger target is identified and combined with the SPAC; until then, the income statement does not provide meaningful insight into long‑term performance.

Balance Sheet

Balance Sheet The balance sheet is very simple and typical for a newly listed SPAC. It mainly consists of cash (or cash‑equivalent assets in a trust account) and shareholder equity, with little to no debt and no operating assets like property, equipment, or inventory. This means the company is financially “light” and relatively low risk from a leverage perspective, but it also has no underlying business assets generating returns yet. The entire balance sheet essentially represents a pool of capital waiting to be deployed into a future acquisition.

Cash Flow

Cash Flow Cash flows today reflect formation and listing activity rather than business operations. There is effectively no operating cash inflow because the company has no revenue‑generating activities, and spending is limited to basic corporate and deal‑related costs. Most of the meaningful cash movement happens around the IPO proceeds going into the trust. Future cash flow patterns—revenues, expenses, investment, and financing—will depend completely on what kind of healthcare company SIMAU eventually acquires and how that combined entity performs.

Competitive Edge

Competitive Edge As a SPAC, SIMAU’s competitive position is not about products or market share; it is about its ability to source and secure an attractive healthcare deal before its deadline. It competes with other SPACs, private equity funds, and strategic buyers all chasing similar targets. The main edge it can claim is the experience and network of its leadership team, including healthcare and intellectual property expertise and high‑profile board members. However, this advantage is hard to quantify, and the real test will be whether they can lock in a strong target at a reasonable valuation in a crowded and regulated environment.

Innovation and R&D

Innovation and R&D SIMAU itself does not conduct research, develop products, or own technology platforms. Its “innovation” is purely financial and structural—it is a vehicle to take another company public. Any real innovation or R&D story will sit inside the healthcare business it ultimately acquires. For now, the only differentiating factor is the team’s background in healthcare and intellectual property, which may help them identify a target with strong scientific or technological foundations. The true R&D profile, pipeline strength, and technological moat will only be known once a merger partner is announced and fully disclosed.

Summary

SIMAU is a classic early‑stage SPAC: no operations, no revenue, a cash‑heavy and simple balance sheet, and financial statements that mainly show the structure of the IPO rather than a functioning business. The core asset is a pool of capital and a management team aiming to acquire a promising healthcare company. Almost all of the future risk and opportunity lies in three things: which target they choose, the price and terms of that deal, and how that acquired business performs over time. Until a merger is announced and detailed, the available financials tell you very little about long‑term earnings power or business quality; they mainly confirm that this is a blank‑check vehicle waiting for its first real move.